Page 120 - TD-3-4

Tumor Discovery Bioinformatics insights into CCL2 mutations

directly or indirectly. Separately, other authors declared doi: 10.1002/mco2.147
that they have no known competing financial interests or 6. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines
personal relationships that could have influenced the work and chemokines: At the crossroads of cell signalling
reported in this paper. and inflammatory disease. Biochim Biophys Acta.
2014;1843(11):2563-2582.
Author contributions
doi: 10.1016/j.bbamcr.2014.05.014
Conceptualization: Shah Kamal, Cheng Deng, Shanshan Lai 7. White GE, Iqbal AJ, Greaves DR. CC chemokine receptors
Formal analysis: Shah Kamal, Amanullah Amanullah, Najeeb and chronic inflammation-therapeutic opportunities
Ullah, Mariam Ahmed Mujtaba, Kashif Ali Khan and pharmacological challenges. Pharmacol Rev.
Investigation: Shah Kamal, Mohammad Amjad Kamal, 2013;65(1):47-89.
Shanshan Lai, Cheng Dend
Methodology: Najeeb Ullah, Shah Kamal, Mariam Ahmed doi: 10.1124/pr.111.005074
Mujtaba, Kashif Ali Khan 8. Dommel S, Blüher M. Does C-C motif chemokine ligand 2
Writing–original draft: Shah Kamal, Cheng Deng, (CCL2) link obesity to a pro-inflammatory state? Int J Mol
Mohammad Amjad Kamal, Shanshan Lai Sci. 2021;22(3):1500.
Writing–review & editing: Shanshan Lai, Mohammad doi: 10.3390/ijms22031500
Amjad Kamal, Najeeb Ullah, Cheng Deng
9. Xu M, Wang Y, Xia R, Wei Y, Wei X. Role of the CCL2-CCR2
Ethics approval and consent to participate signalling axis in cancer: Mechanisms and therapeutic
targeting. Cell Prolif. 2021;54(10):e13115.
Not applicable.
doi: 10.1111/cpr.13115
Consent for publication 10. Ben-Baruch A. Host microenvironment in breast
cancer development: Inflammatory cells, cytokines and
Not applicable.
chemokines in breast cancer progression: Reciprocal
Availability of data tumor-microenvironment interactions. Breast Cancer Res.
2002;5(1):31.
All datasets generated for this study are available from the doi: 10.1186/bcr554
corresponding authors on reasonable request.
11. Yoshimura T, Li C, Wang Y, Matsukawa A. The chemokine
References monocyte chemoattractant protein-1/CCL2 is a
promoter of breast cancer metastasis. Cell Mol Immunol.
1. Zhu S, Liu M, Bennett S, Wang Z, Pfleger KDG, Xu J. The 2023;20(7):714-38.
molecular structure and role of CCL2 (MCP-1) and C-C
chemokine receptor CCR2 in skeletal biology and diseases. doi: 10.1038/s41423-023-01013-0
J Cell Physiol. 2021;236(10):7211-7222. 12. Soria G, Yaal-Hahoshen N, Azenshtein E, et al. Concomitant
doi: 10.1002/jcp.30375 expression of the chemokines RANTES and MCP-1
in human breast cancer: A basis for tumor-promoting
2. Schubert M, Bleuler-Martinez S, Butschi A, et al. Plasticity interactions. Cytokine. 2008;44(1):191-200.
of the β-trefoil protein fold in the recognition and control
of invertebrate predators and parasites by a fungal defence doi: 10.1016/j.cyto.2008.08.002
system. PLoS Pathog. 2012;8(5):e1002706. 13. Furukawa S, Soeda S, Kiko Y, et al. MCP-1 promotes invasion
doi: 10.1371/journal.ppat.1002706 and adhesion of human ovarian cancer cells. Anticancer Res.
2013;33(11):4785-4790.
3. Joshi N, Kumar D, Poluri KM. Elucidating the molecular
interactions of chemokine CCL2 orthologs with flavonoid 14. Hefler L, Tempfer C, Heinze G, et al. Monocyte
baicalin. ACS Omega. 2020;5(35):22637-22651. chemoattractant protein-1 serum levels in ovarian cancer
patients. Br J Cancer. 1999;81(5):855-829.
doi: 10.1021/acsomega.0c03428
doi: 10.1038/sj.bjc.6690776
4. Shao Z, Tan Y, Shen Q, et al. Molecular insights into ligand
recognition and activation of chemokine receptors CCR2 15. Bhat AA, Nisar S, Maacha S, et al. Cytokine-chemokine
and CCR3. Cell Discov. 2022;8(1):44. network driven metastasis in esophageal cancer; promising
avenue for targeted therapy. Mol Cancer. 2021;20:2.
doi: 10.1038/s41421-022-00403-4
doi: 10.1186/s12943-020-01294-3
5. Li H, Wu M, Zhao X. Role of chemokine systems in
cancer and inflammatory diseases. MedComm (2020). 16. Singh S, Anshita D, Ravichandiran V. MCP-1:
2022;3(2):e147. Function, regulation, and involvement in disease. Int

Volume 3 Issue 4 (2024) 22 doi: 10.36922/td.3891